Immunic, Inc. · NASDAQ:IMUX
Immunic — Investor Presentation (November 2026)
47 slides from Immunic's investor presentation, November 2026
Slide 1: Investor Overview
Investor Overview NASDAQ: IMUX November 2026 © Immunic, Inc. | Nov 2026 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Slide 3: Immunic: Pivoting to a Fully Integrated Multiple Sclerosis Company
Immunic: Pivoting to a Fully Integrated Multiple Sclerosis Company Advancing a Potentially Differentiated Oral MS Therapy to Address High Unmet Needs with Near-Term Blockbuster Potential in Relapsing MS and Significant Upside Potential in Progressive MS Near-Term Value Inflection Expansion Opportuni
Slide 4: Vidofludimus Calcium Is Being Developed as a Franchise Opportunity Spanning Relapsing and Progressive MS
Vidofludimus Calcium Is Being Developed as a Franchise Opportunity Spanning Relapsing and Progressive MS PR OGR AM IND IC AT IO N PR E CL INI CAL PH AS E 1 PH AS E 2 PH AS E 3 ST AT US NE XT MI LE S TO NE Vidofludimus Relapsing MS Top-line data for both trials Calcium Both trials fully enrolled ENSU
Slide 5: Leadership Team with Established Multiple Sclerosis Development and Commercialization Experience
Leadership Team with Established Multiple Sclerosis Development and Commercialization Experience Erik Lundgren, MBA Jason Tardio, MBA Glenn Whaley, CPA Hella Kohlhof, PhD Michael A. Panzara, MD, MPH Chief Executive Officer President & Chief Financial Officer Co-Founder & Chief Medical Officer Chief
Slide 6: Vidofludimus Calcium Has the Potential to Transform the MS Market
Vidofludimus Calcium Has the Potential to Transform the MS Market Substantial Opportunities: MS Remains a Large and Growing Market Attractive Market Dynamics ▪ Multiple blockbuster therapies can successfully coexist, reflecting the large patient BLOCKBUSTER POTENTIAL population, heterogenous disease
Slide 7: Key Unmet Needs Remain in Relapsing and Progressive MS
Key Unmet Needs Remain in Relapsing and Progressive MS: The Next Generation of MS Treatments Must Move Beyond Relapse Control Progression Independent Safety and Treatments for Progressive of Relapse Activity (PIRA) Tolerability Multiple Sclerosis ▪ PIRA continues to occur even in patients ▪ Many app
Slide 8: Current DMTs Target Inflammation, None Stop/Reverse Disability Accumulation
Current DMTs Target Inflammation, None Stop/Reverse Disability Accumulation 20+ Therapies Exist for Relapsing MS, None Adequately Address the Neurodegeneration Driving Progression EDSS Disease Trajectory Over Time Bedridden / 9–10 Death from MS focal i nflam ma tion Wheelchair restricted 7–8 Disabil
Slide 9: Vidofludimus Calcium: A Unique Dual Mechanism Approach to MS
Vidofludimus Calcium: A Unique Dual Mechanism Approach to MS Potentially the Only Oral MS Drug Addressing Both PIRA and RAW Simultaneously Direct Nurr1 Activator Selective DHODH Inhibitor ▪ Modulates gene expression directly in ▪ Selectively targets neurons, mediating neuroprotection metabolically h
Slide 10: Addressing Near-Term Unmet Needs in Relapsing Multiple Sclerosis
Addressing Near-Term Unmet Needs in Relapsing Multiple Sclerosis
Slide 11: EMPhASIS: Strong Efficacy, Durable Long-Term Benefit, and Favorable Safety in RRMS
EMPhASIS: Strong Efficacy, Durable Long-Term Benefit, and Favorable Safety and Tolerability in Relapsing-Remitting MS Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial (NCT03846219) 268 patients in 36 centers across four European countries Screening Main Treatment Peri
Slide 12: Robust Reduction in MRI Lesion Activity Over 24 Weeks
Robust Reduction in MRI Lesion Activity Over 24 Weeks Primary and Key Secondary Endpoints Both Highly Statistically Significant, Pooled Cohorts 1&2 Reduction in CUA Lesions up to Week 24 Reduction in Gd+ Lesions up to Week 24 0 0 0 7 0 5 0 -13% -10 -10 6 -20 4 -20 5 -30 -30 4 -40 3 -40 -50 -50 3 -60
Slide 13: Encouraging Trend on Risk of Relapse
Encouraging Trend on Risk of Relapse, Despite Study Size and Short Duration of 24 Weeks 42% Relative risk of relapse reduced by 42% Proportion of patients with relapse relative risk reduction (HR: 0.58, p=0.19) in 30 mg group vs. (HR: 0.58, p=0.19) placebo to Week 24 23% Apparent onset of effect wit
Slide 14: Favorable Safety and Tolerability Profile with Similar Incidence to Placebo
Favorable Safety and Tolerability Profile with Similar Incidence to Placebo Vidofludimus Vidofludimus Safety and Tolerability Endpoints Placebo Calcium 30 mg Calcium 45 mg Key Safety Observations: ▪ No signal for liver injury Any treatment-emergent adverse event 44% 45% 41% Treatment-emergent advers
Slide 15: Open-Label Extension: Durability of Effect Over Time
Open-Label Extension Phase: Durability of Effect Over Time with 92.3% of Patients CDW-Free at 144 Weeks 100.0% 98.0% 97.2% 100% 94.6% 93.3% 93.3% 92.3% 90% › At week 144, 92.3% of patients % Patients Free of 12wCDW Events 80% remained free of 12-week CDW, with 70% 92.7% free of 24-week CDW 60% 50% ›
Slide 16: ENSURE Phase 3: Two Fully Enrolled Pivotal Trials
ENSURE Phase 3: Two Fully Enrolled Pivotal Trials Designed to Confirm Immunomodulatory Effects Specifically Through Relapse Reduction Randomized, Double-Blind, Placebo-Controlled Trials (NCT05134441 & NCT05201638) Screening OLE (optional) Main Treatment Period (Blinded) ▪ More than 100 sites in 15 c
Slide 17: Recruited Patients in ENSURE Similar to Population Recruited into EMPhASIS
Recruited Patients in ENSURE Similar to Population Recruited into EMPhASIS Total of 2,221 Enrolled Patients, Nearly 50% Received Prior MS Treatment ENSURE Baseline Patient Characteristics 1 EMPhASIS Baseline Patient Characteristics ENSURE-1 (N=1,121) ENSURE-2 (N=1,100) EMPhASIS (N=249) 2 Mean age (S
Slide 18: Primary and Secondary Endpoints Selected to Ensure Robust Assessment
Primary and Secondary Endpoints Selected to Ensure Robust Assessment of Clinical and Imaging Outcomes Meaningful to People with MS ENSURE-1 Pooled ENSURE Trials ENSURE-2 “ I hope to see different kinds of MS drugs: ones that stop Primary Primary Time to First Relapse (TTFR) Net Clinical Benefit Time
Slide 19: Net Chance of Benefit: Concept
Net Chance of Benefit: Concept A Pairwise Treatment Effect for Any Outcome, or Several Ranked Outcomes Pairwise comparison of observed outcomes New statistical approach for multiple outcomes ▪ Net chance of benefit: a treatment effect estimate Treated patient (Xi) Control patient (Yj) based on pairw
Slide 20: Vidofludimus Calcium in Relapsing MS: Targeted NDA Submission Driven by Near-Term Pivotal Readouts
Vidofludimus Calcium in Relapsing MS: Targeted NDA Submission Driven by Near-Term Pivotal Readouts › Fully enrolled Phase 3 ENSURE-1 and Robust Phase 2 EMPhASIS Results on Inflammatory Endpoints ENSURE-2 trials with top-line data expected by year-end 2026 › NDA submission in the U.S. targeted for Ph
Slide 21: Potential to Change Treatment Paradigm in Progressive Multiple Sclerosis
Potential to Change Treatment Paradigm in Progressive Multiple Sclerosis
Slide 22: CALLIPER: Phase 2 Clinical Trial in Progressive MS
CALLIPER: Phase 2 Clinical Trial in Progressive MS Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (NCT05054140) 467 Adult Patients Randomized, >340 Patients Continuing in OLE* Inclusion Criteria OLE Screening Main Treatment Period (Blinded) (optional) Period › Patients aged 18 to 65
Slide 23: Patient Demographics and Baseline Characteristics
Patient Demographics and Baseline Characteristics Total Study Population of 467 Enrolled Patients Progressive Disease Subtypes Baseline Patient Characteristics Age [years], median (min-max) 51.0 (21-65) N=47 10.1% Gender (n and % female) 302 (64.7%) N=152 32.5% Race (n and % White) 460 (98.7%) BMI [
Slide 24: Statistical Significance Not Achieved on Primary PBVC Endpoint at Month 30
Statistical Significance Not Achieved on Primary PBVC Endpoint at Month 30, Although Encouraging Trends on Regional Atrophy Re-Baselined at 6 Months 0 Primary Endpoint: Relative difference of Vidofludimus Calcium annual PBVC rate at 30 months: 4.7%; Placebo -0.2 95% CI, -0.285 to 0.379; P=0.78 Regio
Slide 25: Favorable Trends Across Exploratory Disability Outcomes Through Week 120
Favorable Trends Across Exploratory Disability Outcomes Through Week 120 with a Nominally Significant Effect in CDI 24wCDW 24wCDI Favors Favors Hazard Ratio Favors Favors Hazard Ratio VidoCa/PBO VidoCa Placebo (95% CI) VidoCa/PBO Placebo VidoCa (95% CI) All Subjects 235/232 0.76 (0.48–1.21) 235/232
Slide 26: Exploratory MRI Endpoint: Mean Volume Change in New/Enlarging T2 Lesions
Exploratory MRI Endpoint Through Week 96 Mean Volume Change in New/Enlarging T2 Lesions 0.4 › Mean absolute volume of VidoCa Mean Absolute Change from Baseline new/enlarging T2 lesions through 0.3 Placebo week 96: A nominal significant reduction in T2 lesion volume was 0.2 seen at weeks 48, 72, and
Slide 27: Exploratory MRI Endpoint: Slowly Expanding Lesions
Exploratory MRI Endpoint Through Week 96 Mean Change from Baseline in Number of Slowly Expanding Lesions (SELs) 4 › The mean number of newly detected SELs VidoCa increased over time in both groups but was lower 3.5 Mean Change from Baseline Placebo with vidofludimus calcium than placebo 3 throughout
Slide 28: Favorable Trends Across Exploratory Disability Outcomes Maintained Into Open-Label Extension
Favorable Trends Across Exploratory Disability Outcomes Maintained Into Open-Label Extension Exploratory 24-Week CDW and CDI Outcomes by Subgroup Through OLE Cut-off 24wCDW – OLE ITT 24wCDI– OLE ITT Favors Favors Hazard Ratio Favors Favors Hazard Ratio VidoCa–VidoCa PBO–VidoCa VidoCa–VidoCa PBO–Vido
Slide 29: Net Clinical Benefit: 1.5x More Likely to Have a Beneficial Disability Outcome
Net Clinical Benefit: Vidofludimus Calcium Treated Patients Were 1.5x More Likely to Have a Beneficial Disability Outcome Total Pairs Wins Losses Ties Win % Loss % Tie % Win Ratio 54520 12552 8284 33684 23.02% 15.19% 61.78% 1.51 Losses 8,284 W I N R AT I O Wins 12,552 (wins) 12,552 WR = = 1.51 8,284
Slide 30: Favorable Safety and Tolerability Profile Through Week 120
Favorable Safety and Tolerability Profile Through Week 120 Five Most Common TEAEs Placebo (n=232) 45 mg Vidofludimus Calcium (n=235) Urinary tract infection 36 (15.5) 39 (16.6) Headache 16 (6.9) 10 (4.3) › No new safety signals observed Back pain 17 (7.4) 9 (3.8) during main treatment period Fall 11
Slide 31: PROTECT-MS
PROTECT-MS Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate Efficacy, Safety, and Tolerability of IMU-838 (Vidofludimus Calcium) in Participants with Progressive Multiple Sclerosis
Slide 32: PROTECT-MS Study Population
PROTECT-MS Study Population Key Inclusion Criteria: + Age 18-65 + Non-active SPMS or PPMS PROTECT-MS will evaluate the + No disease activity (relapses or new MRI lesions) in the prior 2 years spectrum of progressive MS by + Disability progression documented in the prior year enrolling people with no
Slide 33: PROTECT-MS Study Design
PROTECT-MS Study Design Key Objective: Study design is not final and is subject to change. CDW: confirmed disability worsening To determine if vidofludimus calcium impacts disability progression in people with progressive MS Screening Period Main Period Optional Extension Period Vidofludimus calcium
Slide 34: PROTECT-MS Study Endpoints
PROTECT-MS Study Endpoints Primary Endpoint: Time to 24-Week Confirmed Disability Worsening (CDW) or 9HPT Secondary and Exploratory Endpoints Disability Imaging PROs Confirmed disability improvement (CDI) Slowly expanding lesions (SEL) Quality of life Net clinical benefit (impact on CDW & CDI) Param
Slide 35: Vidofludimus Calcium in Progressive MS: Treatment Paradigm Changing Potential
Vidofludimus Calcium in Progressive MS: Treatment Paradigm Changing Potential Strong Imaging and Exploratory Disability Phase 2 Efficacy Signals* Initiation of Phase 3 PROTECT-MS trial Favorable and Consistent Safety Profile at 45 mg Dose › in progressive MS ongoing, with first- patient-enrolled exp
Slide 36: Commercial Opportunity
Commercial Opportunity
Slide 37: The U.S. Relapsing MS Market is Large, Continues to Grow, and Oral DMTs Remain a Sizable Class
The U.S. Relapsing MS Market is Large, Continues to Grow, and Oral DMTs Remain a Sizable Class ~7% CAGR Total U.S. Relapsing MS Patient Share by Class2 ~$25B 51% anti-CD20 ~$17B 28% Orals 2025 13% Platform injectables 8% Other high-efficacy mAbs 2026 2032 Sales numbers in G7 countries (U.S., UK, Can
Slide 38: Not a Winner Take All Market: ~90K U.S. Patients Making a Treatment Decision Each Year
Not a Winner Take All Market: Dynamic with ~90K U.S. Patients Making a Treatment Decision Each Year, with Another ~125K Currently Untreated THE RELAPSING MS PATIENT JOURNEY CREATES MULTIPLE TREATMENT DECISION POINTS relapsing MS patients initiate ~45K therapy each year1 01 02 03 04 INI TI ATE SWITCH
Slide 39: Vidofludimus Calcium Is Targeted to Deliver the Optimal Balance of Treatment Attributes
Vidofludimus Calcium Is Targeted to Deliver the Optimal Balance of the Treatment Attributes That Matter Most to Patients and HCPs Safety Neuroprotection/Anti-inflammation Potentially reduces key safety concerns Combines neuroprotective effects through associated with currently marketed DMTs, Nurr1 a
Slide 40: Vidofludimus Calcium Could Address Several Large, Underserved Relapsing MS Patient Segments
Vidofludimus Calcium Could Address Several Large, Underserved Relapsing MS Patient Segments Treated Relapsing Addressable Patient Segments for Size of Opportunity MS Patients Vidofludimus Calcium Relapsing MS Patients who Patients seeking ~75K relapsing MS ▪ A favorable risk-benefit Patients who con
Slide 41: Vidofludimus Calcium Has the Potential to Address Significant Opportunities in Relapsing MS
Vidofludimus Calcium Has the Potential to Address Significant Opportunities in Relapsing MS LARGE AND GROWING MARKET NOT A WINNER-TAKE-ALL MARKET 1 The U.S. relapsing MS market is ~$17B today and projected to reach ~$25B by 2032, with oral DMTs remaining a significant treatment class 2 Patients init
Slide 42: Success in Progressive MS Represents a Multi-Billion-Dollar Long-Term Commercial Opportunity
Success in Progressive MS Represents a Multi-Billion-Dollar Long-Term Commercial Opportunity With Significant Growth Potential United States Europe/UK ~175K diagnosed cases of SPMS and PPMS ~165K diagnosed cases of SPMS and PPMS ~115K SPMS and PPMS patients receiving DMTs ~58K SPMS and PPMS patients
Slide 43: Summary and Outlook
Summary and Outlook
Slide 44: Building a Leading MS Company: A Phased Commercial Strategy
Building a Leading MS Company: A Phased Commercial Strategy Relapsing MS Establishes Commercial Foundation; Progressive MS Drives Long-Term Value Creation BECOME A GLOBAL MS LEADER (2032+) SCALE & GENERATE CASH FLOW Capture a substantially larger market (2028-2032) opportunity through expansion into
Slide 45: Value Creation Roadmap
Value Creation Roadmap Multiple Catalysts Through 2030 2H 2026 2027 2028 Relapsing MS ENSURE-1 and ENSURE-2 Top-line data expected Targeted relapsing MS NDA Potential relapsing MS U.S. in December 2026 submission in mid-2027 regulatory approval in 2028 Progressive MS Initiation of Phase 3 trial Firs
Slide 46: Immunic: Pivoting to a Fully Integrated Multiple Sclerosis Company
Immunic: Pivoting to a Fully Integrated Multiple Sclerosis Company Advancing a Potentially Differentiated Oral MS Therapy to Address High Unmet Needs with Near-Term Blockbuster Potential in Relapsing MS and Significant Upside Potential in Progressive MS Near-Term Value Inflection Expansion Opportuni
Slide 47: Thank you!
Thank you! Jessica Breu Vice President Investor Relations & Communications Immunic, Inc. Immunic AG Immunic Australia Pty. Ltd. Phone: +1-332-255-9819 1200 Avenue of the Americas Lochhamer Schlag 21 Melbourne Email: ir@imux.com New York, NY 10036 82166 Gräfelfing (Munich) Australia Web: www.imux.com